Clinical Research Directory
Browse clinical research sites, groups, and studies.
Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
Sponsor: Abramson Cancer Center at Penn Medicine
Summary
The purpose of this research study is to determine if frailty assessments can be used to predict how well patients aged 60 years and older will do after chemotherapy, CAR T-cell therapy, or allogeneic stem cell transplant.
Official title: Prospective Analysis of Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
Key Details
Gender
All
Age Range
60 Years - Any
Study Type
OBSERVATIONAL
Enrollment
20
Start Date
2018-09-21
Completion Date
2026-11
Last Updated
2025-07-31
Healthy Volunteers
No
Conditions
Interventions
Bone Marrow or Peripheral Blood Graft (BMT)
Patient receives bone marrow or peripheral blood graft (BMT) on or off protocol.
Cancer-directed Therapy or Best Supportive Care
Cancer-directed therapy with intensive regimens ("7+3," Vyxeos, clofarabine, or similar), clinical trial, hypomethylating agent (azacitidine or decitabine), hypomethylating agent combinations (i.e. with venetoclax, sorafenib, enasidenib, ivosidenib, midostaurin, gilteritinib, or other targeted agent), targeted agents alone (i.e. enasidenib, ivosidenib, gilteritinib, midostaurin, etc.), or supportive care.
Frailty Assessment
Frailty is the vulnerability of older adults to adverse health outcomes in response to illness and iatrogenic stressors.
Locations (1)
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States